Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Kailera completed enrollment in all three KaiNETIC global Phase 3 trials of ribupatide injection for obesity/overweight. Topline data from KaiNETIC-1, -2, and -3 are expected in mid-2028.Material DetailsContext by AI AnalystThis is a mid-to-late development milestone confirming program execution to…
Kailera Therapeutics completed enrollment in its global Phase 3 KaiNETIC program testing once-weekly ribupatide injection, with topline data expected mid-2028.
Kailera Therapeutics announced completion of enrollment in KaiNETIC, its global Phase 3 clinical program of ribupatide injection, a GLP-1/GIP receptor dual agonist.